CommercialDocumentationLow impact
07.00.21k, Allergy Immunotherapy
Independence Blue Cross·Allergy & Immunology, Internal Medicine, Family Medicine +1 more·Medical Policy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued policy 07.00.21k on allergy immunotherapy, effective 10/20/2025, with clarified terminology: the policy now references a 'build-up phase' and 'maintenance phase' instead of 'escalation phase,' and removes the 1cc aliquot requirement. The coverage criteria and medically necessary services remain unchanged. Billing teams should verify their documentation templates and system rules align with the phase terminology used in this reissued policy.
Action Required
By October 20, 2025: Review internal documentation templates, encounter forms, and billing system rules to ensure terminology reflects the updated phases (build-up phase and maintenance phase) rather than escalation phase. No changes to CPT or HCPCS code usage are required (95115, 95117, 95120, 95125, 95165, G0069, G0089 remain medically necessary). Providers and billing staff should be informed of the terminology update to ensure consistent medical record documentation. Update any internal policy quick-reference guides or training materials. The removal of the 1cc aliquot requirement does not affect billing but may affect allergy extract preparation workflows—coordinate with clinical staff if applicable.